Acebutolol
Ruxolitinib may increase the bradycardic activities of Acebutolol.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Ruxolitinib.
Amiodarone
The serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone.
Advertisement
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Ruxolitinib.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Anthrax immune globulin human.
Advertisement
Apalutamide
The serum concentration of Ruxolitinib can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Ruxolitinib can be increased when it is combined with Aprepitant.
Atazanavir
The serum concentration of Ruxolitinib can be increased when it is combined with Atazanavir.
Advertisement
Atenolol
Ruxolitinib may increase the bradycardic activities of Atenolol.
Atomoxetine
The metabolism of Ruxolitinib can be decreased when combined with Atomoxetine.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ruxolitinib.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin substrain tice live antigen.
Bendroflumethiazide
Ruxolitinib may increase the bradycardic activities of Bendroflumethiazide.
Beractant
Ruxolitinib may increase the bradycardic activities of Beractant.
Betaxolol
Ruxolitinib may increase the bradycardic activities of Betaxolol.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Ruxolitinib.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Ruxolitinib.
Bisoprolol
Ruxolitinib may increase the bradycardic activities of Bisoprolol.
Boceprevir
The serum concentration of Ruxolitinib can be increased when it is combined with Boceprevir.
Bortezomib
The metabolism of Ruxolitinib can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Ruxolitinib can be decreased when it is combined with Bosentan.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.
Calfactant
Ruxolitinib may increase the bradycardic activities of Calfactant.
Carbamazepine
The metabolism of Ruxolitinib can be increased when combined with Carbamazepine.
Carteolol
Ruxolitinib may increase the bradycardic activities of Carteolol.
Carvedilol
Ruxolitinib may increase the bradycardic activities of Carvedilol.
Ceritinib
The serum concentration of Ruxolitinib can be increased when it is combined with Ceritinib.
Clarithromycin
The serum concentration of Ruxolitinib can be increased when it is combined with Clarithromycin.
Clemastine
The metabolism of Ruxolitinib can be decreased when combined with Clemastine.
Clonidine
Ruxolitinib may increase the bradycardic activities of Clonidine.
Clotrimazole
The metabolism of Ruxolitinib can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clozapine.
Cobicistat
The serum concentration of Ruxolitinib can be increased when it is combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Ruxolitinib.
Crizotinib
Ruxolitinib may increase the bradycardic activities of Crizotinib.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Ruxolitinib.
Cyclosporine
The metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Ruxolitinib can be decreased when it is combined with Dabrafenib.
Darunavir
The serum concentration of Ruxolitinib can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Ruxolitinib can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Ruxolitinib can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Ruxolitinib can be decreased when combined with Delavirdine.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Ruxolitinib.
Dexmedetomidine
Ruxolitinib may increase the bradycardic activities of Dexmedetomidine.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Ruxolitinib.
Digoxin
Ruxolitinib may increase the bradycardic activities of Digoxin.
Dihydroergotamine
The metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.
Diltiazem
Ruxolitinib may increase the bradycardic activities of Diltiazem.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Ruxolitinib.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.
Donepezil
Ruxolitinib may increase the bradycardic activities of Donepezil.
Doxycycline
The metabolism of Ruxolitinib can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Ruxolitinib can be decreased when combined with Doxycycline.
Dronedarone
Ruxolitinib may increase the bradycardic activities of Dronedarone.
Enzalutamide
The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.
Erythromycin
The metabolism of Ruxolitinib can be decreased when combined with Erythromycin.
Esmolol
Ruxolitinib may increase the bradycardic activities of Esmolol.
Fingolimod
Ruxolitinib may increase the immunosuppressive activities of Fingolimod.
Fluconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Fluconazole.
Fluvoxamine
The metabolism of Ruxolitinib can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Ruxolitinib can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Ruxolitinib can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Ruxolitinib can be increased when combined with Fosphenytoin.
Fusidate
The serum concentration of Ruxolitinib can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Ruxolitinib can be increased when it is combined with Fusidic Acid.
Galantamine
Ruxolitinib may increase the bradycardic activities of Galantamine.
Guanfacine
Ruxolitinib may increase the bradycardic activities of Guanfacine.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Hepatitis B Vaccine (Recombinant).
Hypoxis hemerocallidea root extract
The serum concentration of Ruxolitinib can be decreased when it is combined with St. John's Wort.
Idelalisib
The serum concentration of Ruxolitinib can be increased when it is combined with Idelalisib.
Imatinib
The metabolism of Ruxolitinib can be decreased when combined with Imatinib.
Indinavir
The serum concentration of Ruxolitinib can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Ruxolitinib can be increased when it is combined with Indinavir.
Isavuconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Ruxolitinib can be decreased when combined with Isavuconazonium.
Isradipine
The metabolism of Ruxolitinib can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Itraconazole.
Ivabradine
Ruxolitinib may increase the bradycardic activities of Ivabradine.
Ivacaftor
The serum concentration of Ruxolitinib can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Ketoconazole.
Labetalol
Ruxolitinib may increase the bradycardic activities of Labetalol.
Lanreotide
Ruxolitinib may increase the bradycardic activities of Lanreotide.
Leflunomide
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Leflunomide.
Levobunolol
Ruxolitinib may increase the bradycardic activities of Levobunolol.
Lopinavir
The serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir.
Lovastatin
The metabolism of Ruxolitinib can be decreased when combined with Lovastatin.
Lucinactant
Ruxolitinib may increase the bradycardic activities of Lucinactant.
Luliconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Ruxolitinib can be increased when combined with Lumacaftor.
Methyldopa
Ruxolitinib may increase the bradycardic activities of Methyldopa.
METHYLDOPA ANHYDROUS
Ruxolitinib may increase the bradycardic activities of Methyldopa.
Metipranolol
Ruxolitinib may increase the bradycardic activities of Metipranolol.
Metoprolol
Ruxolitinib may increase the bradycardic activities of Metoprolol.
Mifepristone
The serum concentration of Ruxolitinib can be increased when it is combined with Mifepristone.
Mitotane
The serum concentration of Ruxolitinib can be decreased when it is combined with Mitotane.
Nadolol
Ruxolitinib may increase the bradycardic activities of Nadolol.
Natalizumab
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.
Nebivolol
Ruxolitinib may increase the bradycardic activities of Nebivolol.
Nefazodone
The serum concentration of Ruxolitinib can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir.
Netupitant
The serum concentration of Ruxolitinib can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Ruxolitinib can be increased when combined with Nevirapine.
Nilotinib
The metabolism of Ruxolitinib can be decreased when combined with Nilotinib.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Ruxolitinib.
Octreotide
Ruxolitinib may increase the bradycardic activities of Octreotide.
Olaparib
The metabolism of Ruxolitinib can be decreased when combined with Olaparib.
Osimertinib
The serum concentration of Ruxolitinib can be increased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Ruxolitinib.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ruxolitinib.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ruxolitinib.
Palbociclib
The serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib.
Pasireotide
Ruxolitinib may increase the bradycardic activities of Pasireotide.
Penbutolol
Ruxolitinib may increase the bradycardic activities of Penbutolol.
Pentobarbital
The metabolism of Ruxolitinib can be increased when combined with Pentobarbital.
Phenobarbital
The metabolism of Ruxolitinib can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Ruxolitinib can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ruxolitinib.
Pindolol
Ruxolitinib may increase the bradycardic activities of Pindolol.
Poractant alfa
Ruxolitinib may increase the bradycardic activities of Poractant alfa.
Posaconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Posaconazole.
Primidone
The metabolism of Ruxolitinib can be increased when combined with Primidone.
Propafenone
Ruxolitinib may increase the bradycardic activities of Propafenone.
Propranolol
Ruxolitinib may increase the bradycardic activities of Propranolol.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Ruxolitinib.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rabies virus inactivated antigen, A.
Ranolazine
The metabolism of Ruxolitinib can be decreased when combined with Ranolazine.
Rifabutin
The metabolism of Ruxolitinib can be increased when combined with Rifabutin.
Rifampin
The metabolism of Ruxolitinib can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Ruxolitinib can be increased when combined with Rifapentine.
Rivastigmine
Ruxolitinib may increase the bradycardic activities of Rivastigmine.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Ruxolitinib.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rubella virus vaccine.
Rucaparib
The metabolism of Ruxolitinib can be decreased when combined with Rucaparib.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Salmonella typhi ty21a live antigen.
Saquinavir
The serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Ruxolitinib can be decreased when used in combination with Sarilumab.
Sildenafil
The metabolism of Ruxolitinib can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Ruxolitinib can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Ruxolitinib can be increased when it is combined with Simeprevir.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.
Sotalol
Ruxolitinib may increase the bradycardic activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Ruxolitinib can be decreased when it is combined with St. John's Wort.
Sufentanil
Ruxolitinib may increase the bradycardic activities of Sufentanil.
Sulfisoxazole
The metabolism of Ruxolitinib can be decreased when combined with Sulfisoxazole.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Ruxolitinib.
Telaprevir
The serum concentration of Ruxolitinib can be increased when it is combined with Telaprevir.
Telithromycin
The serum concentration of Ruxolitinib can be increased when it is combined with Telithromycin.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Ticlopidine
The metabolism of Ruxolitinib can be decreased when combined with Ticlopidine.
Timolol
Ruxolitinib may increase the bradycardic activities of Timolol.
Timolol Anhydrous
Ruxolitinib may increase the bradycardic activities of Timolol.
Tizanidine
Ruxolitinib may increase the bradycardic activities of Tizanidine.
Tocilizumab
The serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab.
Tofacitinib
Ruxolitinib may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Ruxolitinib.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Ruxolitinib can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Ruxolitinib can be decreased when combined with Venlafaxine.
Verapamil
Ruxolitinib may increase the bradycardic activities of Verapamil.
Voriconazole
The serum concentration of Ruxolitinib can be increased when it is combined with Voriconazole.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Yellow Fever Vaccine.
Ziprasidone
The metabolism of Ruxolitinib can be decreased when combined with Ziprasidone.
